Presentation is loading. Please wait.

Presentation is loading. Please wait.

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report 

Published byれんか たつざわ Modified over 5 years ago

Similar presentations

Presentation on theme: "Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report "— Presentation transcript:

1 Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report  Joline S.W. Lind, MBBS, MA, Pieter E. Postmus, MD, PhD, Egbert F. Smit, MD, PhD  Journal of Thoracic Oncology  Volume 5, Issue 4, Pages (April 2010) DOI: /JTO.0b013e3181d3e47e Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Axial, contrast-enhanced computed tomography (CT) image of the thorax before erlotinib showed (A) an osteolytic bone metastases in the right acromium (arrow). (B) Three months after starting erlotinib, increased osteosclerosis was seen at the site of this metastasis (arrow). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d3e47e) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Axial, contrast-enhanced computed tomography (CT) image of the thorax at the time of diagnosis showed (A) an osteolytic bone metastasis in the 12th thoracic vertebra (arrow). A CT scan after 6 weeks of erlotinib treatment showed (B) osteoblastic activity in the metastasis of the 12th thoracic vertebra (arrow) and (D) an osteoblastic lesion in the third thoracic vertebra (arrow) not visible at baseline (C). Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d3e47e) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Axial, contrast-enhanced computed tomography (CT) image of the thorax before low-dose erlotinib showed (A) osteolytic bone metastases in the sternum and thoracic vertebra (arrows) and (B) mild osteoblastic activity in the lumbar vertebra (arrow). A CT scan after 10 weeks of erlotinib treatment showed (B) marked osteoblastic activity in the sternum (arrow), osteosclerosis around the metastases in the thoracic vertebrae (arrow), and (D) diffuse, increased osteosclerosis in the lumbar vertebra. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d3e47e) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report "

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib  C. Leitner, R. von Moos,

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib  C. Leitner, R. von Moos,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.
MET Mutation Associated with Responsiveness to Crizotinib

MET Mutation Associated with Responsiveness to Crizotinib
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma

Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A
Joline S. W. Lind, MBBS, Egbert F

Joline S. W. Lind, MBBS, Egbert F
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.

Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.
Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy  Elizabeth Gore, MD, Adam Currey, MD, Nicholas Choong,

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy  Elizabeth Gore, MD, Adam Currey, MD, Nicholas Choong,

Similar presentations

Ads by Google